Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ROCC, KBAL, ADAP, TCRR

ADAP

NEW YORK, April 11, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Halper Sadeh LLC (PRNewsfoto/Halper Sadeh LLP)

Ranger Oil Corporation (NASDAQ: ROCC)'s sale to Baytex Energy Corp. Under the terms of the agreement, Ranger shareholders will receive 7.49 Baytex shares plus $13.31 in cash, for each Ranger common share. If you are a Ranger shareholder, click here to learn more about your rights and options.

Kimball International, Inc. (NASDAQ: KBAL)'s sale to HNI Corporation for $9.00 in cash and 0.1301 shares of HNI common stock for each share of Kimball common stock. If you are a Kimball shareholder, click here to learn more about your rights and options.

Adaptimmune Therapeutics plc (NASDAQ: ADAP)'s merger with TCR² Therapeutics Inc. Under the terms of the agreement, TCR² stockholders will receive 1.5117 Adaptimmune ADS for each TCR² share. Following the closing of the transaction, Adaptimmune shareholders will own approximately 75% of the combined company. If you are a Adaptimmune shareholder, click here to learn more about your rights and options.

TCR² Therapeutics Inc. (NASDAQ: TCRR)'s sale to Adaptimmune Therapeutics plc for 1.5117 Adaptimmune ADS for each TCR² share is fair to TCR² shareholders. Following the closing of the transaction, TCR² stockholders will own approximately 25% of the combined company. If you are a TCR² shareholder, click here to learn more about your rights and options.

Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-update-halper-sadeh-llc-investigates-rocc-kbal-adap-tcrr-301794508.html

SOURCE Halper Sadeh LLP